glp-1 and liver Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty disease (NAFLD): A systematic review - Lv - 2020 - Endocrinology, Diabetes & Metabolism Glucagon-like peptide-1 and glucagon-like peptide-2

Have a conversation with your healthcare provider about weight loss medications, how they work, and their potential risks

K., Tso, S

But a study published in the Journal of Clinical Endocrinology and Metabolism by Buse and colleagues found no evidence that tolerance develops toward liraglutide glucose-lowering effects in humans

Drugs that increase potassium levels: Elevated serum potassium is more likely when spironolactone is combined with drugs that have the potential to increase blood potassium levels

Health regulatory agencies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) evaluate data from clinical trials before approving the use of GLP-1 analogs for the treatment of diabetes and obesity